4.5 Article

Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation

期刊

ELECTROPHORESIS
卷 27, 期 11, 页码 2111-2125

出版社

WILEY
DOI: 10.1002/elps.200500827

关键词

biomarker; capillary electrophoresis; mass spectrometry; peptides; tandem mass spectrometry

资金

  1. NIDCR NIH HHS [DE13694] Funding Source: Medline
  2. NIDDK NIH HHS [DK61525, DK57750] Funding Source: Medline
  3. NIGMS NIH HHS [R01 GM098539] Funding Source: Medline

向作者/读者索取更多资源

CE-MS is a successful proteomic platform for the definition of biomarkers in different body fluids. Besides the biomarker defining experimental parameters, CE migration time and molecular weight, especially biomarker's sequence identity is an indispensable cornerstone for deeper insights into the pathophysiological pathways of diseases or for made-to-measure therapeutic drug design. Therefore, this report presents a detailed discussion of different peptide sequencing platforms consisting of high performance separation method either coupled on-line or off-line to different MS/MS devices, such as MALDI-TOF-TOF ESI-IT, ESI-QTOF and Fourier transform ion cyclotron resonance, for sequencing indicative peptides. This comparison demonstrates the unique feature of CE-MS technology to serve as a reliable basis for the assignment of peptide sequence data obtained using different separation MS/MS methods to the biomarker defining parameters, CE migration time and molecular weight. Discovery of potential biomarkers by CE-MS enables sequence analysis via MS/MS with platform-independent sample separation. This is due to the fact that the number of basic and neutral polar amino acids of biomarkers sequences distinctly correlates with their CE-MS migration time/molecular weight coordinates. This uniqueness facilitates the independent entry of different sequencing platforms for peptide sequencing of CE-MS-defined biomarkers from highly complex mixtures.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据